Side Effects of Levothyroxine
The primary side effects of levothyroxine stem from overtreatment (iatrogenic hyperthyroidism) and include cardiac complications—particularly atrial fibrillation, angina, and arrhythmias—along with bone loss, and symptoms of thyrotoxicosis such as palpitations, anxiety, tremors, insomnia, heat intolerance, and weight loss. 1
Overtreatment-Related Side Effects
The FDA label explicitly warns that levothyroxine has a narrow therapeutic index, meaning the margin between therapeutic and toxic doses is small 1. When TSH is suppressed below normal ranges (particularly <0.1 mIU/L), patients face:
Cardiovascular Complications
- Increased heart rate, cardiac wall thickness, and contractility
- Atrial fibrillation (2.8 to 5-fold increased risk when TSH <0.1 mIU/L) 2
- Angina or myocardial infarction, especially in elderly patients or those with pre-existing cardiovascular disease 1
- Increased cardiovascular mortality (up to 3-fold in patients >60 years) 2
Critical caveat: Elderly patients and those with coronary artery disease are at highest risk and require lower starting doses 1.
Skeletal Effects
- Accelerated bone loss and decreased bone mineral density in postmenopausal women with TSH <0.1 mIU/L 2
- Increased fracture risk (hip and spine) in women >65 years when TSH ≤0.1 mIU/L 2
- Craniosynostosis and accelerated bone age in children with overtreatment 1
Hyperthyroid Symptoms
Research demonstrates that during initial levothyroxine therapy, patients commonly experience 3, 4:
- Palpitations (occurring 14.1 ± 0.93 days out of 15 days)
- Sweating (9.6 ± 1.14 days out of 15 days)
- Anxiety/agitation
- Headache
- Tremors, nervousness, insomnia
- Heat intolerance
- Weight loss despite increased appetite
- Diarrhea
- Menstrual irregularities 1
Undertreatment-Related Effects
When dosing is inadequate (TSH remains elevated):
- Persistent hypothyroid symptoms (fatigue, cognitive impairment)
- In children: impaired cognitive development and linear growth 1
- Continued cardiovascular risk from untreated hypothyroidism
Metabolic and Systemic Effects
Oxidative Stress
Recent research shows levothyroxine therapy increases oxidative stress markers, with hydroperoxide levels rising from 370 to 435 U.CARR during treatment 4. This oxidative stress correlates with side effect severity and causes daily discomfort in approximately one-third of treatment days 4.
Glucose Metabolism
- Worsening glycemic control in diabetic patients
- Increased insulin or antidiabetic medication requirements 1
Adrenal Crisis Risk
In patients with undiagnosed adrenal insufficiency, levothyroxine can precipitate acute adrenal crisis by increasing glucocorticoid clearance 1. This is why uncorrected adrenal insufficiency is an absolute contraindication 1.
Rare but Serious Side Effects
Hepatotoxicity
Case reports document drug-induced liver injury with levothyroxine, particularly when doses are increased too rapidly 5. Liver enzymes normalized after cessation and improved with slower titration.
Cancer Risk
A large retrospective study (601,733 cases) found levothyroxine users had 50% higher risk of cancer at any site (AOR: 1.50), with particularly elevated risks for brain (AOR: 1.90), skin (AOR: 1.42), pancreatic (AOR: 1.27), and breast cancer (AOR: 1.24) 6. However, this association requires confirmation and may reflect confounding by indication.
Pregnancy-Specific Considerations
The risks of appropriately managed levothyroxine therapy in pregnancy are minimal 2. However:
- Levothyroxine requirements typically increase during pregnancy
- TSH should be monitored every 6-8 weeks with dose adjustments as needed 2
- Undertreatment poses greater fetal risks (neuropsychological complications, fetal wastage) than appropriate treatment 2
Minimizing Side Effects: Practical Algorithm
Start low in high-risk patients: Use lower initial doses in elderly patients, those with cardiovascular disease, or long-standing hypothyroidism 1
Titrate slowly: Adjust doses gradually based on TSH monitoring at 6-8 week intervals 1
Target appropriate TSH range: Aim for TSH within reference range (not necessarily lower half unless symptomatic) 2
Monitor for cardiac symptoms: If palpitations, chest pain, or arrhythmias develop, reduce dose or withhold for one week and restart at lower dose 1
Address absorption issues: Administer on empty stomach, at least 4 hours apart from interfering medications 1
Screen for adrenal insufficiency before initiating therapy in at-risk patients 1
Common pitfall: Overtreating to achieve TSH in the lower reference range without clinical indication increases cardiovascular and skeletal risks without proven benefit 2.